Patients with a healed duodenal ulcer and who were symptom-free following 12 months of maintenance treatment with cimetidine 400 mg twice daily were randomized double-blind to a further 6 months therapy with either cimetidine 400 mg twice daily or placebo 2 tablets twice daily. Twenty-six patients received placebo and 15 patients cimetidine. Relapse was defined as symptoms for 3 out of 7 consecutive days and ulcer recurrence was confirmed by independent endoscopy. One of 15 patients on cimetidine relapsed: 20 of 26 patients on placebo relapsed. This relapse rate (77%) is similar to that found in previous studies after only 6 weeks cimetidine therapy (71%). This study suggests that 12 months cimetidine does not change the tendency of duodenal ulcer to recur and that the relapse rate is no greater than after 6 weeks cimetidine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01308302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of rain garden runoff control effects based on multiple machine learning techniques.
Environ Technol
January 2025
Shaanxi Huashan Road and Bridge Group Co., Ltd., Xi'an, People's Republic of China.
Due to the rapid development of urbanisation, cities frequently experience waterlogging during rainfall. Rain gardens are widely used in new urban construction because they effectively control surface runoff from rainwater, thereby reducing waterlogging. The runoff control effectiveness of rain gardens is influenced by multiple factors.
View Article and Find Full Text PDFThe Southern Brazilian Registry of Atrial Fibrillation (SBR-AF Registry): Predictors of Atrial Arrhythmia Recurrence after First-Time Catheter Ablation.
Arq Bras Cardiol
January 2025
Serviço de Arritmia Cardíaca, Hospital SOS Cardio, Florianópolis, SC - Brasil.
Background: Treatment of atrial fibrillation (AF) with catheter ablation (CA) has evolved significantly. However, real-world data on long-term outcomes are limited, particularly in low- and middle-income countries.
Objective: This multicenter prospective cohort of consecutive patients aimed to evaluate the safety and efficacy of first-time CA for AF in Southern Brazil from 2009 to 2024.
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
January 2025
Roswell Park Cancer Institute, Buffalo, NY, United States.
Background: Data in clear cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of HIF1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC.
Patients And Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment).
SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.
J Cancer Res Clin Oncol
January 2025
Key Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Purpose: Growing evidence suggests that the tyrosine phosphatase SHP2 is pivotal for tumor progression. Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer, characterized by its high recurrence rate, aggressive metastasis, and resistance to chemotherapy. Understanding the mechanisms of tumorigenesis and the underlying molecular pathways in TNBC could aid in identifying new therapeutic targets.
View Article and Find Full Text PDFFeasibility, Safety, and Impact of Awake Resection for Recurrent Insular Diffuse Gliomas in Adults.
Neurosurgery
January 2025
Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Paris, France.
Background And Objectives: The risk-to-benefit ratio of transopercular awake resection for recurrent insular diffuse gliomas is poorly studied. We assessed feasibility, safety, and efficacy of awake surgical resection of recurrent insular diffuse gliomas in patients with previous treatments (resection and/or radiotherapy and/or chemotherapy and/or combination).
Methods: Observational, retrospective, single-institution cohort analysis (2010-2023) of 123 consecutive adult patients operated on for an insular diffuse glioma (2021 World Health Organization classification) under awake conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!